Effect of Sitagliptin on serum adiponectin levels in type 2 diabetic patients and the relationship with Body Mass Index
Abstract
The prevalence of type 2 diabetes mellitus around the world has greatly worsened during the last two decades, infection with this disease leads to the development of many serious complications over time, at the level of both small and large blood vessels. Insulin resistance plays a major role in the development of type 2 diabetes and Reducing this resistance is a therapeutic strategy aimed at limiting the progression of type 2 diabetes and other metabolic disorders which are associated with this resistance. Adipose tissue plays a role as a metabolically active endocrine gland through the secretion of a group of mediators called adipokines, including adiponectin, which has properties that increase tissue sensitivity to insulin Thus, the search for compounds that increase the levels of this adipokine may be a new therapeutic tool to reduce the development of diseases associated with insulin resistance. Multiple studies have been conducted to investigate the effect of sitagliptin, a member of the group of DPP-4 inhibitors, on adiponectin, but the results were inconsistent. Therefore, in this study, we examined the effect of sitagliptin on serum adiponectin levels.
The study was conducted on a number of patients with type 2 diabetes attending the Endocrinology Clinic at Tishreen University Hospital. They were distributed into two groups: First group (the control group) included newly diagnosed patients who received metformin treatment, whereas the second group (the sitagliptin group), included patients diagnosed previously with type 2 diabetes for a period of 3 months or more, who were undergoing treatment with metformin, then sitagliptin was added to their treatment plan. the follow-up period lasted for 3 months. Fasting blood glucose, glycated hemoglobin, body mass index, and plasma adiponectin levels were measured.
At the end of the study, a statistically significant increase in adiponectin levels was observed in both groups, and this increase was higher in metformin group (the control group) without statistically significant difference between the two groups. Therefore, the addition of sitagliptin to the treatment plan as an add-on therapy to metformin leads to an improvement in glucose control, but it does not play a significant role in raising serum adiponectin levels compared to treatment by metformin alone.
On the other hand, this study showed that the addition of sitagliptin as an add-on therapy to metformin in (sitagliptin group) led to an increase in serum levels of adiponectin, and this increase was greater and statistically significant in patients with BMI (≥30 kg/m²) compared to patients with BMI (<30 kg/m²), and this statistical significance appeared in (sitagliptin group) only. without observing any significant statistical difference in (control group).
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.